Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Of The Week: Mylan/Agila, UCB/Biotie, Jazz/Concert…

Executive Summary

Elan peels off assets to attract suitors: First Biogen buys out Elan’s 50% interest in Tysabri, then Royalty Pharma maneuvers to buy out Elan.

You may also be interested in...



Leo Pharma Gets Patient-Centric On The Frontiers Of Psoriasis

Denmark’s dermatology specialist Leo Pharma has linked up with a U.S. psoriasis patient group, the National Psoriasis Foundation, to target innovation on unmet clinical needs.

Resolve Scores The Option Of An Exit With Takeda Tie-Up

Resolve Therapeutics and Takeda Pharmaceuticals have agreed to an option agreement that will add to the Japanese pharma’s immunology pipeline while also providing a path to an eventual exit for the biotech’s investors.

Jazz And Concert In Tune On Xyrem

The two biotech companies have teamed up to create a follow-on product to Jazz’s narcolepsy drug, a collaboration that could add to the patent-life of Xyrem and be financially beneficial for both companies.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS055159

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel